However, as shown by Harrison et al., BUDCA treatment had no significant impact on serum FGF-19 or fibrotic indicators such as propeptide type III collagen (Pro-C3) and Enhanced Liver Fibrosis (ELF) score [68]. The gene discussed is FGF19; the disease is Hepatic fibrosis.